Global study identifies markers for the five clinical stages of Parkinson's disease
From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Oklahoma Medical Research Foundation receives $3 million grant for Parkinson's research
The Oklahoma Medical Research Foundation has received a $3 million grant to study Parkinson's disease, potentially leading to ...
MedPage Today8d
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
WFMZ-TV10d
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
GLP-1 drugs like Ozempic do not slow Parkinson's disease, study finds The trial showed no benefit in symptoms or brain scans Experts say more research is needed before using these drugs for brain ...
KTBS10d
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class ...